Dr. George Tetz, MD, PhD, Human Microbiology Institute, NY, USA, is an invited speaker at Antibiotics Webinar | Antibiotics vs. Phage Therapy 10 May 2021
This webinar is focused on the comparison and interplay between antibiotics and phage therapy. George Tetz, will be giving a talk on the ole pf phages as possible human pathogens. https://www.mdpi.com/journal/antibiotics/events
Abstract Title: Bacterial DNA Promotes Tau and Beta-amyloid Aggregation and Is Suggested as a Novel Therapeutic Target for Alzheimer’s Disease
Our abstract was accepted for an iPoster presentation at the #WorldMicrobeForum! Plan to see me online from June 20-24! Visit the website for details: https://bit.ly/3mLJcg1
New York, NY – July 22, 2020) – A New-York city-based start-up TGV-Dx was selected a winner in the special COVID-19 edition of the “Make Your Medical Device Pitch for Kids!” competition presented by FDA-sponsored National Capital Consortium for Pediatric Device Innovation. The competition focused on innovations in COVID-19-related pediatric medical devices that will improve children’s health care, with 16 finalists competing in a virtual pitch event for a share of $250,000 in total grant awards. TGV-Dx received a grant award as a result of their winning presentation
WASHINGTON, July 14, 2020 /PRNewswire/ — Sixteen finalists are announced in the “Make Your Medical Device Pitch for Kids!” special COVID-19 edition competition presented by the National Capital Consortium for Pediatric Device Innovation (NCC-PDI). Representing innovations in COVID-19-related pediatric medical devices, the finalists will compete in a virtual pitch event held on July 20, 2020.
Interview to Forbes : SARS-CoV-2 Prion-Like Domains in Spike Proteins Enable Higher Affinity to ACE2
In the interview to Forbes Dr. George Tetz highlights possible major scientific breakthroughs based on his article “SARS-CoV-2 Prion-Like Domains in Spike Proteins Enable Higher Affinity to ACE2”
The full text is available at: https://www.forbes.com/sites/jvchamary/2020/04/17/prion-like-coronavirus/#6ea4b8df4680
Human Microbiology Institute commits expertise and assets to the fight against COVID-19 pandemic
New York, March 19, 2020 — Today, Human Microbiology Institute (HMI) announced that it accelerates the development of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. HMI brings a range of breakthrough resources and expertise needed to identify novel therapeutic targets within SARS-VoC-2 for the new solutions to the pandemic
HMI’s abstract was accepted for a poster presentation at the Microbiome Innovation Summit that will be held at The Jackson Laboratory on Friday November 1, 2019 and The Jackson Laboratory in Farmington, CT.
This year’s program will feature an outstanding diversity of speakers addressing a wide range of important topics in microbiome science across many disciplines. Speakers and panel discussions will address:
HMI as a Member The New York Academy of Sciences is honored to participate at the Academy’s 201st Annual Meeting.
During the event special guests for a by-invitation-only screening of Jim Allison: Breakthrough (2019), the inspirational story of one scientist’s quest to find a cure for cancer. Today, Academy Member James P. Allison is well-known for receiving the 2018 Nobel Prize in Physiology or Medicine jointly with Japanese immunologist Tasuku Honjo for their discovery of cancer therapies that stimulate the immune system to attack tumor cells. This gripping documentary follows Dr. Allison’s life and work over several decades, and provides insight into what it means to struggle against skepticism and resistance in order to achieve the extraordinary. A Q&A session with Bill Haney, the film’s director, was followed the screening.
Our presentation “ Bacterial DNA promotes Tau aggregation” has been selected as an oral report at the Society for Neurosciences 2019, October 19-23, Chicago, IL.
